Literature DB >> 10855791

Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.

M C Gong1, S S Chang, M Sadelain, N H Bander, W D Heston.   

Abstract

Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein that is expressed by prostate epithelial cells. PSMA-specific monoclonal antibodies have been utilized to characterize the biologic function and in vivo biodistribution of PSMA. PSMA is an attractive target protein for monoclonal antibody directed imaging or therapeutics for prostate cancer since its expression is relatively restricted to prostate epithelial cells and is over-expressed in prostate cancer, including in advanced stages. Currently, clinical usage of PSMA specific monoclonal antibodies has been limited to diagnostic immunohistochemistry and imaging of patients with prostate cancer. Novel applications for these antibodies will be discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10855791     DOI: 10.1023/a:1006308826967

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  16 in total

1.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.

Authors:  Mindy I Davis; Melanie J Bennett; Leonard M Thomas; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

2.  A comprehensive mathematical model for three-body binding equilibria.

Authors:  Eugene F Douglass; Chad J Miller; Gerson Sparer; Harold Shapiro; David A Spiegel
Journal:  J Am Chem Soc       Date:  2013-04-16       Impact factor: 15.419

Review 3.  Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.

Authors:  Sagnik Sengupta; Mena Asha Krishnan; Sudeshna Chattopadhyay; Venkatesh Chelvam
Journal:  Cancer Rep (Hoboken)       Date:  2019-04-02

4.  Overview of prostate-specific membrane antigen.

Authors:  Sam S Chang
Journal:  Rev Urol       Date:  2004

Review 5.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

6.  A low molecular weight PSMA-based fluorescent imaging agent for cancer.

Authors:  Ying Chen; Surajit Dhara; Sangeeta Ray Banerjee; Youngjoo Byun; Mrudula Pullambhatla; Ronnie C Mease; Martin G Pomper
Journal:  Biochem Biophys Res Commun       Date:  2009-10-08       Impact factor: 3.575

7.  Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.

Authors:  Chunsheng Liu; Kosei Hasegawa; Stephen J Russell; Michel Sadelain; Kah-Whye Peng
Journal:  Prostate       Date:  2009-07-01       Impact factor: 4.104

8.  Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.

Authors:  Vojtech Klusák; Cyril Barinka; Anna Plechanovová; Petra Mlcochová; Jan Konvalinka; Lubomír Rulísek; Jacek Lubkowski
Journal:  Biochemistry       Date:  2009-05-19       Impact factor: 3.162

9.  A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.

Authors:  Greta Giordano-Attianese; Pablo Gainza; Elise Gray-Gaillard; Elisabetta Cribioli; Sailan Shui; Seonghoon Kim; Mi-Jeong Kwak; Sabrina Vollers; Angel De Jesus Corria Osorio; Patrick Reichenbach; Jaume Bonet; Byung-Ha Oh; Melita Irving; George Coukos; Bruno E Correia
Journal:  Nat Biotechnol       Date:  2020-02-03       Impact factor: 54.908

10.  Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages.

Authors:  Olcay Boyacioglu; Christopher H Stuart; George Kulik; William H Gmeiner
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-16       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.